লোডিং...

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data m...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:J Clin Oncol
প্রধান লেখক: Rush, Hannah L., Murphy, Laura, Morgans, Alicia K., Clarke, Noel W., Cook, Adrian D., Attard, Gerhardt, Macnair, Archie, Dearnaley, David P., Parker, Christopher C., Russell, J. Martin, Gillessen, Silke, Matheson, David, Millman, Robin, Brawley, Christopher D., Pugh, Cheryl, Tanguay, Jacob S., Jones, Robert J., Wagstaff, John, Rudman, Sarah, O'Sullivan, Joe M., Gale, Joanna, Birtle, Alison, Protheroe, Andrew, Gray, Emma, Perna, Carla, Tolan, Shaun, McPhail, Neil, Malik, Zaf I., Vengalil, Salil, Fackrell, David, Hoskin, Peter, Sydes, Matthew R., Chowdhury, Simon, Gilbert, Duncan C., Parmar, Mahesh K. B., James, Nicholas D., Langley, Ruth E.
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: 2022
বিষয়গুলি:
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612717/
https://ncbi.nlm.nih.gov/pubmed/34757812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00728
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!